Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.56 |
| ▸ | HTR2C known ✓ | P28335 | 9/20 | 0.50 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 0.47 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.47 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.46 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30611185 | 1.00 | SLC6A4 (0.57) | SLC6A4HTR6APPHTR2CCAMK2D | |
| SCHEMBL5937271 | 0.98 | HTR6 (0.57) | SLC6A4HTR6APPHTR2CCAMK2D | |
| SCHEMBL1890136 | 0.89 | HTR6 (0.50) | SLC6A4HTR6APPCAMK2DPRKCG | |
| SCHEMBL17067795 | 0.87 | ALDH1A1 (0.51) | SLC6A4LMNAKMT2AUSP2ALDH1A1 | |
| SCHEMBL28127883 | 0.83 | ALDH1A1 (0.49) | SLC6A4LMNAKMT2AUSP2ALDH1A1 | |
| SCHEMBL28779618 | 0.82 | RAB9A (0.48) | SLC6A4LMNAKMT2AUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28061385 | 0.81 | HTR6 (0.56) | SLC6A4HTR6HTR2CCAMK2DADRB2 | |
| SCHEMBL1893232 | 0.81 | HTR6 (0.60) | SLC6A4HTR6HTR2CCAMK2DLMNA | |
| Hydrochloric Acid SCHEMBL30611179 | 0.80 | SLC6A4 (0.64) | SLC6A4HTR6APPALDH1A1 | |
| Hydrochloric Acid SCHEMBL26912351 | 0.80 | SLC6A4 (0.64) | SLC6A4HTR6APPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| CN-1921859-A | Indole derivatives for the treatment of bone diseases | ASTELLAS PHARMA INC (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
| US-4100291-A | HYPOTENSIVE | ROUSSEL UCLAF (FR) | 1978-07-11 | — | — | US | disclosed |
| US-3993764-A | 3-(4*-PIPERIDYL)-INDOLES | ROUSSEL-UCLAF (FR) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | SLC6A4 1968/4885HTR6 1013/4885HTR2C 1504/4885 |
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | SLC6A4 3523/4885HTR6 3737/4885HTR2C 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.